

TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT



	Dr. Vinay Chopra MD (Pathology & Micr Chairman & Consultar	obiology)	MD	n Chopra D (Pathology) t Pathologist
NAME	: Mr. RAMESH CHAND			
AGE/ GENDER	: 45 YRS/MALE		PATIENT ID	: 1786923
COLLECTED BY	:		REG. NO./LAB NO.	: 012503110018
REFERRED BY	:		REGISTRATION DATE	: 11/Mar/2025 09:29 AM
BARCODE NO.	:01526914		COLLECTION DATE	: 11/Mar/2025 09:35AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 11/Mar/2025 09:58AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMB	ALA CANTI		
Test Name		Value	Unit	Biological Reference interval
				_
			LLNESS PANEL: 1.	5
		PLETE BL	OOD COUNT (CBC)	
	<u>S (RBCS) COUNT AND INDICES</u>	14.0		10.0 17.0
IAEMOGLOBIN (H by CALORIMETRIC	В)	14.2	gm/dL	12.0 - 17.0
RED BLOOD CELL (RBC) COUNT	4.54	Millions	/cmm 3.50 - 5.00
PACKED CELL VOLU		42.6	%	40.0 - 54.0
•	utomated hematology analyzer AR VOLUME (MCV)	93.9	fL	80.0 - 100.0
by CALCULATED BY A	UTOMATED HEMATOLOGY ANALYZER		IL	
	AR HAEMOGLOBIN (MCH) UTOMATED HEMATOLOGY ANALYZER	31.4	pg	27.0 - 34.0
	AR HEMOGLOBIN CONC. (MCHC) UTOMATED HEMATOLOGY ANALYZER	33.4	g/dL	32.0 - 36.0
RED CELL DISTRIB	UTION WIDTH (RDW-CV)	14.4	%	11.00 - 16.00
	utomated hematology analyzer UTION WIDTH (RDW-SD)	50.4	fL	35.0 - 56.0
by CALCULATED BY A	UTOMATED HEMATOLOGY ANALYZER			
MENTZERS INDEX by CALCULATED		20.68	RATIO	BETA THALASSEMIA TRAIT: < 13.0
				IRON DEFICIENCY ANEMIA:
GREEN & KING IND	IFX	29.9	RATIO	>13.0 BETA THALASSEMIA TRAIT:<=
by CALCULATED	JEA	20.0	KATIO	65.0
				IRON DEFICIENCY ANEMIA: > 65.0
WHITE BLOOD CE	LLS (WBCS)			05.0
	E COUNT (TLC)	4110	/cmm	4000 - 11000
	Y BY SF CUBE & MICROSCOPY	NH		0.00 - 20.00
by FLOW CYTOMETRY	I OOD CELLS (nRRCS)			0.00 - 20.00
by FLOW CYTOMETRY NUCLEATED RED B by AUTOMATED 6 PAF	LOOD CELLS (nRBCS) RT HEMATOLOGY ANALYZER LOOD CELLS (nRBCS) %	NIL NIL	%	< 10 %





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







Dr. Yugam Chopra

MD (Pathology & Microbiology) MD (Pathology) Chairman & Consultant Pathologist **CEO & Consultant Pathologist** NAME : Mr. RAMESH CHAND **AGE/ GENDER** : 45 YRS/MALE **PATIENT ID** :1786923 **COLLECTED BY** :012503110018 REG. NO./LAB NO. **REFERRED BY REGISTRATION DATE** :11/Mar/2025 09:29 AM **BARCODE NO. COLLECTION DATE** :11/Mar/2025 09:35AM :01526914 CLIENT CODE. : KOS DIAGNOSTIC LAB **REPORTING DATE** :11/Mar/2025 09:58AM **CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT Test Name Value Unit **Biological Reference interval DIFFERENTIAL LEUCOCYTE COUNT (DLC) NEUTROPHILS** 62 % 50 - 70 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY LYMPHOCYTES 30 % 20 - 40 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY EOSINOPHILS 2 % 1 - 6 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY MONOCYTES 6 % 2 - 12by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY 0 BASOPHILS % 0 - 1 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY **IMMATURE GRANULOCTE (IG) %** 0 % 0 - 5.0 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY **ABSOLUTE LEUKOCYTES (WBC) COUNT** ABSOLUTE NEUTROPHIL COUNT 2548 2000 - 7500 /cmm by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY ABSOLUTE LYMPHOCYTE COUNT 800 - 4900 1233/cmm by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY ABSOLUTE EOSINOPHIL COUNT 82 40 - 440 /cmm by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY ABSOLUTE MONOCYTE COUNT 247 /cmm 80 - 880 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY ABSOLUTE BASOPHIL COUNT 0 0 - 110 /cmm by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY ABSOLUTE IMMATURE GRANULOCYTE COUNT 0 /cmm 0.0 - 999.0 by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY PLATELETS AND OTHER PLATELET PREDICTIVE MARKERS. 150000 - 450000 PLATELET COUNT (PLT) 145000^L /cmm by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE PLATELETCRIT (PCT) 0.21 % 0.10 - 0.36 by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE MEAN PLATELET VOLUME (MPV) 15^H fL 6.50 - 12.0 by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE 77000 30000 - 90000 PLATELET LARGE CELL COUNT (P-LCC) /cmm by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE PLATELET LARGE CELL RATIO (P-LCR) 60.1^H % 11.0 - 45.0 by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE

Dr. Vinay Chopra



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)







	Dr. Vinay Cho MD (Pathology & M Chairman & Consu	1icrobiology)		(Pathology)
NAME	: Mr. RAMESH CHAND			
AGE/ GENDER	: 45 YRS/MALE		PATIENT ID	: 1786923
COLLECTED BY	:		REG. NO./LAB NO.	: 012503110018
REFERRED BY	:		REGISTRATION DATE	: 11/Mar/2025 09:29 AM
BARCODE NO.	:01526914		COLLECTION DATE	: 11/Mar/2025 09:35AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 11/Mar/2025 09:58AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AN	MBALA CANT	Т	
Test Name		Value	Unit	Biological Reference interval
	BUTION WIDTH (PDW) FOCUSING, ELECTRICAL IMPEDENCE	16.8	%	15.0 - 17.0
ADVICE		KINDLY	Y CORRELATE CLINICALI	.Y

NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD

RECHECKED





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)







REGISTI COLLECT	F ID ./LAB NO. RATION DATE FION DATE 'ING DATE	: 1786923 : 012503110018 : 11/Mar/2025 09:29 AM : 11/Mar/2025 09:35AM
REG. NO. REGISTI COLLECT REPORT	./LAB NO. RATION DATE FION DATE	: 012503110018 : 11/Mar/2025 09:29 AM
REGISTE COLLECT REPORT	RATION DATE	: 11/Mar/2025 09:29 AM
COLLECT REPORT	FION DATE	
REPORT		: 11/Mar/2025 09:35AM
	ING DATE	
		: 11/Mar/2025 12:06PM
Value	Unit	Biological Reference interval
LATED HAEMOGL	OBIN (HBA1C)	
5.2	%	4.0 - 6.4
102.54	mg/dL	60.00 - 140.00
SSOCIATION (ADA):		
	/IOGLOGIB (HBAIC) in %	6
<5.7		
5.7	7 – 6.4	
	-	
	> Age > Goals of Therapy: Actions Suggested:	>= 6.5 Age > 19 Years Goals of Therapy: < 7.0

COMMENTS:

TEST PERFORMED AT KOS DIAGNOSTIC LAB. AMBALA CANTT

1.Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients.

2.Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.

3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropriate. 4. High

HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications 5. Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7.Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)


DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







: 6349/1, NICHOLSON ROAD, AN		
. NOS DIAGNOSTIC LAD	NEI ONTING DITTE	
· KOS DIACNOSTIC LAB	REPORTING DATE	: 11/Mar/2025 12:06PM
: 01526914	COLLECTION DATE	: 11/Mar/2025 09:35AM
:	REGISTRATION DATE	: 11/Mar/2025 09:29 AM
:	REG. NO./LAB NO.	: 012503110018
: 45 YRS/MALE	PATIENT ID	: 1786923
: Mr. RAMESH CHAND		
	G, /	D (Pathology) nt Pathologist
		m Chopra
	MD (Pathology & N Chairman & Consu : Mr. RAMESH CHAND : 45 YRS/MALE : : : 01526914	MD (Pathology & Microbiology) Chairman & Consultant Pathologist CEO & Consultant : Mr. RAMESH CHAND : 45 YRS/MALE PATIENT ID : REG. NO./LAB NO. : REGISTRATION DATE





DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)







	Dr. Vinay Che MD (Pathology & Chairman & Cons		m Chopra D (Pathology) nt Pathologist
IAME	: Mr. RAMESH CHAND		
AGE/ GENDER	: 45 YRS/MALE	PATIENT ID	: 1786923
COLLECTED BY	:	REG. NO./LAB NO.	: 012503110018
REFERRED BY	:	REGISTRATION DATE	: 11/Mar/2025 09:29 AM
BARCODE NO.	: 01526914	COLLECTION DATE	: 11/Mar/2025 09:35AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	: 11/Mar/2025 10:21AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, A	AMBALA CANTT	
Test Name		Value Unit	Biological Reference interval
	ERYTHR DIMENTATION RATE (ESR) GATION BY CAPILLARY PHOTOMETR	OCYTE SEDIMENTATION RATE 5 mm/1s Y	(ESR)





DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

Page 6 of 21





	٨		& Microbiology) sultant Pathologis		(Pathology)
NAME	: Mr. RAMESH	CHAND			
AGE/ GENDER	: 45 YRS/MALE			PATIENT ID	: 1786923
COLLECTED BY	:			REG. NO./LAB NO.	: 012503110018
REFERRED BY	:			REGISTRATION DATE	: 11/Mar/2025 09:29 AM
BARCODE NO.	:01526914			COLLECTION DATE	: 11/Mar/2025 09:35AM
CLIENT CODE.	: KOS DIAGNOS	STIC LAB		REPORTING DATE	: 11/Mar/2025 11:38AM
CLIENT ADDRESS	: 6349/1, NICH	IOLSON ROAD,	AMBALA CANTT		
Test Name			Value	Unit	Biological Reference interval
		CLINI	CAL CHEMIS	TRY/BIOCHEMIST	'RY
			GLUCOSE	FASTING (F)	
GLUCOSE FASTIN	G (F): PLASMA Se - peroxidase (G	OD-POD)	108.98 ^H	mg/dL	NORMAL: < 100.0 PREDIABETIC: 100.0 - 125.0

IN ACCORDANCE WITH AMERICAN DIABETES ASSOCIATION GUIDELINES:

A fasting plasma glucose level below 100 mg/dl is considered normal.
 A fasting plasma glucose level between 100 - 125 mg/dl is considered as glucose intolerant or prediabetic. A fasting and post-prandial blood test (after consumption of 75 gms of glucose) is recommended for all such patients.

test (after consumption of 75 gms of glucose) is recommended for all such patients. 3. A fasting plasma glucose level of above 125 mg/dl is highly suggestive of diabetic state. A repeat post-prandial is strongly recommended for all such patients. A fasting plasma glucose level in excess of 125 mg/dl on both occasions is confirmatory for diabetic state.





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com
 www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.





	Dr. Vinay Cł MD (Pathology & Chairman & Cor		Dr. Yugam MD CEO & Consultant	(Pathology)
NAME	: Mr. RAMESH CHAND			
AGE/ GENDER	: 45 YRS/MALE	PATI	ENT ID	: 1786923
COLLECTED BY	:	REG.	NO./LAB NO.	: 012503110018
REFERRED BY	:	REGI	STRATION DATE	: 11/Mar/2025 09:29 AM
BARCODE NO.	: 01526914	COLL	ECTION DATE	: 11/Mar/2025 09:35AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPO	RTING DATE	: 11/Mar/2025 01:03PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD,	AMBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
		LIPID PROFIL	E : BASIC	
CHOLESTEROL TO	TAL: SERUM	239.92 ^H	mg/dL	OPTIMAL: < 200.0
by CHOLESTEROL O		239.92~	ing, dL	BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0
TRIGLYCERIDES: S by GLYCEROL PHOSE	ERUM phate oxidase (enzymatic)	192.86 ^H	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0
				VERY HIGH: $> OR = 500.0$
HDL CHOLESTERO by SELECTIVE INHIBIT	L (DIRECT): SERUM Ton	56.76	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 - 60.0 HIGH HDL: > OR = 60.0
LDL CHOLESTEROI by CALCULATED, SPE		144.59 ^H	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0
NON HDL CHOLES by Calculated, spe		183.16 ^H	mg/dL	VERY HIGH: > OR = 190.0 OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERV HIGH: + OR = 220.0
VLDL CHOLESTER		38.57	mg/dL	VERY HIGH: > OR = 220.0 0.00 - 45.00
by CALCULATED, SPE TOTAL LIPIDS: SEE by CALCULATED. SPE	RUM	672.7	mg/dL	350.00 - 700.00
CHOLESTEROL/HE by CALCULATED, SPE	DL RATIO: SERUM	4.23	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0



DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: Ilnd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.





	Dr. Vinay Ch MD (Pathology & Chairman & Cor	& Microbiology)		(Pathology)
NAME	: Mr. RAMESH CHAND			
AGE/ GENDER	: 45 YRS/MALE		PATIENT ID	: 1786923
COLLECTED BY	:		REG. NO./LAB NO.	: 012503110018
REFERRED BY	:		REGISTRATION DATE	: 11/Mar/2025 09:29 AM
BARCODE NO.	:01526914		COLLECTION DATE	: 11/Mar/2025 09:35AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 11/Mar/2025 01:03PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD,	AMBALA CANT	Т	
Test Name		Value	Unit	Biological Reference interval
LDL/HDL RATIO: S by CALCULATED, SPE		2.55	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/H by CALCULATED, SPE	IDL RATIO: SERUM ECTROPHOTOMETRY	3.4	RATIO	3.00 - 5.00

INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

 Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
 NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







	Dr. Vinay Chop MD (Pathology & Mic Chairman & Consulta	crobiology)		(Pathology)
NAME	: Mr. RAMESH CHAND			
AGE/ GENDER	: 45 YRS/MALE		PATIENT ID	: 1786923
COLLECTED BY	:		REG. NO./LAB NO.	: 012503110018
REFERRED BY	:		REGISTRATION DATE	: 11/Mar/2025 09:29 AM
BARCODE NO.	:01526914		COLLECTION DATE	: 11/Mar/2025 09:35AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 11/Mar/2025 01:03PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMI	BALA CANTT		
Test Name		Value	Unit	Biological Reference interval
	LIVER	FUNCTION	N TEST (COMPLETE)	
BILIRUBIN TOTAL by DIAZOTIZATION, SI	: SERUM pectrophotometry	1.14	mg/dL	INFANT: 0.20 - 8.00 ADULT: 0.00 - 1.20
	(CONJUGATED): SERUM	0.22	mg/dL	0.00 - 0.40
BILIRUBIN INDIRE	CCT (UNCONJUGATED): SERUM	0.92	mg/dL	0.10 - 1.00
SGOT/AST: SERUM	[/RIDOXAL PHOSPHATE	23	U/L	7.00 - 45.00
SGPT/ALT: SERUM		22.4	U/L	0.00 - 49.00
AST/ALT RATIO: S by CALCULATED, SPE		1.03	RATIO	0.00 - 46.00
ALKALINE PHOSPI		84.41	U/L	40.0 - 130.0
GAMMA GLUTAMY by SZASZ, SPECTRO	L TRANSFERASE (GGT): SERUM	19.26	U/L	0.00 - 55.0
TOTAL PROTEINS: by BIURET, SPECTRO	SERUM	7.93	gm/dL	6.20 - 8.00
ALBUMIN: SERUM by BROMOCRESOL G		4.4	gm/dL	3.50 - 5.50
GLOBULIN: SERUN by CALCULATED, SPE	1	3.53 ^H	gm/dL	2.30 - 3.50
A : G RATIO: SERUI		1.25	RATIO	1.00 - 2.00

by CALCULATED, SPECTROPHOTOMETRY

NOTE: To be correlated in individuals having SGOT and SGPT values higher than Normal Referance Range. USE: Differential diagnosis of diseases of hepatobiliary system and pancreas.

INCREASED:

DRUG HEPATOTOXICITY	> 2
ALCOHOLIC HEPATITIS	> 2 (Highly Suggestive)
CIRRHOSIS	1.4 - 2.0
INTRAHEPATIC CHOLESTATIS	> 1.5
HEPATOCELLULAR CARCINOMA & CHRONIC HEPATITIS	> 1.3 (Slightly Increased)





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



INTERPRETATION





	Dr. Vinay Chopra MD (Pathology & Microbi Chairman & Consultant Pa		(Pathology)
NAME	: Mr. RAMESH CHAND		
AGE/ GENDER	: 45 YRS/MALE	PATIENT ID	: 1786923
COLLECTED BY	:	REG. NO./LAB NO.	: 012503110018
REFERRED BY	:	REGISTRATION DATE	: 11/Mar/2025 09:29 AM
BARCODE NO.	:01526914	COLLECTION DATE	: 11/Mar/2025 09:35AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	: 11/Mar/2025 01:03PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA	CANTT	

DECREASED:

1. Acute Hepatitis due to virus, drugs, toxins (with AST increased 3 to 10 times upper limit of normal)

2. Extra Hepatic cholestatis: 0.8 (normal or slightly decreased).

NORMAL	< 0.65
GOOD PROGNOSTIC SIGN	0.3 - 0.6
POOR PROGNOSTIC SIGN	1.2 - 1.6



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)







00 0001 . 2000 CENT				
	Dr. Vinay Cho MD (Pathology & M Chairman & Consu	1icrobiology)	Dr. Yugam C MD (Pa CEO & Consultant Pa	athology)
NAME	: Mr. RAMESH CHAND			
AGE/ GENDER	: 45 YRS/MALE	PAT	IENT ID	: 1786923
COLLECTED BY	:	REG.	NO./LAB NO.	:012503110018
REFERRED BY	:	REG	ISTRATION DATE	: 11/Mar/2025 09:29 AM
BARCODE NO.	: 01526914	COLI	LECTION DATE	: 11/Mar/2025 09:35AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REP	ORTING DATE	: 11/Mar/2025 01:03PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, A	MBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
	KIDNI	EY FUNCTION TI	EST (COMPLETE)	
UREA: SERUM	MATE DEHYDROGENASE (GLDH)	21.86	mg/dL	10.00 - 50.00
CREATININE: SER	UM	1.16	mg/dL	0.40 - 1.40
-	CTROPHOTOMETERY ROGEN (BUN): SERUM	10.21	mg/dL	7.0 - 25.0
by CALCULATED, SPI	ECTROPHOTOMETRY	10.21	iiig/ uL	
	ROGEN (BUN)/CREATININE	8.8 ^L	RATIO	10.0 - 20.0
RATIO: SERUM by CALCULATED, SPI	ECTROPHOTOMETRY			
UREA/CREATININ		18.84	RATIO	
URIC ACID: SERUM	ECTROPHOTOMETRY [5.41	mg/dL	3.60 - 7.70
by URICASE - OXIDAS				
CALCIUM: SERUM by ARSENAZO III, SPE	ECTROPHOTOMETRY	9.8	mg/dL	8.50 - 10.60
PHOSPHOROUS: SI	ERUM	3.5	mg/dL	2.30 - 4.70
by PHOSPHOMOLYBI	DATE, SPECTROPHOTOMETRY			
SODIUM: SERUM	VE ELECTRODE)	139.8	mmol/L	135.0 - 150.0
POTASSIUM: SERU by ISE (ION SELECTIV	M	4.17	mmol/L	3.50 - 5.00
CHLORIDE: SERUN by ISE (ION SELECTIV	Λ	104.85	mmol/L	90.0 - 110.0
	MERULAR FILTERATION RATE			
ESTIMATED GLOM (eGFR): SERUM by CALCULATED INTERPRETATION:	IERULAR FILTERATION RATE	79.2		
To differentiate betu	wan pro and past ranal azatamia			

To differentiate between pre- and post renal azotemia.

INCREASED RATIO (>20:1) WITH NORMAL CREATININE:

1. Prerenal azotemia (BUN rises without increase in creatinine) e.g. heart failure, salt depletion, dehydration, blood loss) due to decreased glomerular filtration rate.

2. Catabolic states with increased tissue breakdown.

3. GI haemorrhage.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)







AGE/ GENDER : COLLECTED BY : REFERRED BY : BARCODE NO. : CLIENT CODE. :	Mr. RAMESH CHAND 45 YRS/MALE	PATIENT ID REG. NO./LAB	: 178692	/3
COLLECTED BY:REFERRED BY:BARCODE NO.:CLIENT CODE.:	45 YRS/MALE			23
BARCODE NO. : CLIENT CODE. :		REG. NO./LAB		
CLIENT CODE. :			NO. : 01250	3110018
BARCODE NO.		REGISTRATIO		r/2025 09:29 AM
CLIENT CODE. :	01526914	COLLECTION I		r/2025 09:35AM
	KOS DIAGNOSTIC LAB	REPORTING D		r/2025 01:03PM
	6349/1, NICHOLSON ROAD, AME			/ 2023 01:001 10
LIENI ADDRESS .	53497 1, MCHOLSON KOAD, AMIL	SALA CANT I		
Test Name		Value	Unit	Biological Reference interval
DECREASED RATIO (<10:1 1. Acute tubular necrosis 2. Low protein diet and s 3. Severe liver disease. 4. Other causes of decre 5. Repeated dialysis (ure 6. Inherited hyperammo 7. SIADH (syndrome of ir 8. Pregnancy. DECREASED RATIO (<10:1 1. Phenacimide therapy 2. Rhabdomyolysis (releated 3. Muscular patients whith INAPPROPIATE RATIO: 1. Diabetic ketoacidosis should produce an incre	tarvation. ased urea synthesis. tea rather than creatinine diffuses nemias (urea is virtually absent in happropiate antidiuretic harmone)) WITH INCREASED CREATININE: (accelerates conversion of creatin ases muscle creatinine). o develop renal failure. (acetoacetate causes false increa ased BUN/creatinine ratio). y (interferes with creatinine measu R FILTERATION RATE: 	n blood).) due to tubular secretion of u ne to creatinine). se in creatinine with certain i	methodologies,resulti	
<u></u>	Kidney damage with	>90	Presence of P	rotein,
G2	normal or high GFR		Albumin or cas	t in urine
G3a	Mild decrease in GFR	60 -89	Albumin or cas	t in urine
			Albumin or cas	t in urine



DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







	Dr. Vinay Chopr MD (Pathology & Mic Chairman & Consulta	robiology) MD	n Chopra D (Pathology) at Pathologist
NAME	: Mr. RAMESH CHAND		
AGE/ GENDER	: 45 YRS/MALE	PATIENT ID	: 1786923
COLLECTED BY	:	REG. NO./LAB NO.	: 012503110018
REFERRED BY	:	REGISTRATION DATE	: 11/Mar/2025 09:29 AM
BARCODE NO.	:01526914	COLLECTION DATE	: 11/Mar/2025 09:35AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	: 11/Mar/2025 01:03PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AME	BALA CANTT	
Test Name		Value Unit	Biological Reference interval

COMMENTS:

Estimated Glomerular filtration rate (eGFR) is the sum of filtration rates in all functioning nephrons and so an estimation of the GFR provides a measure of functioning nephrons of the kidney.
 eGFR calculated using the 2009 CKD-EPI creatinine equation and GFR category reported as per KDIGO guideline 2012
 In patients, with eGFR creatinine between 45-59 ml/min/1.73 m2 (G3) and without any marker of Kidney damage, It is recommended to measure of CFD with the commended to measure

3. In patients, with eGFR cleaning between 45-59 minimit 1.73 m2 (G3) and without any marker of Kidney damage, it is recommended to measure eGFR with Cystatin C for confirmation of CKD
4. eGFR category G1 OR G2 does not fulfill the criteria for CKD, in the absence of evidence of Kidney Damage
5. In a suspected case of Acute Kidney Injury (AKI), measurement of eGFR should be done after 48-96 hours of any Intervention or procedure
6. eGFR calculated by Serum Creatinine may be less accurate due to certain factors like Race, Muscle Mass, Diet, Certain Drugs. In such cases, eGFR should be calculated using Serum Cystatin C
7. A decrease in eGFR implies either progressive renal disease, or a reversible process causing decreased nephron function (eg, severe dehydration).

ADVICE:

KDIGO guideline, 2012 recommends Chronic Kidney Disease (CKD) should be classified based on cause, eGFR category and Albuminuria (ACR) category. GFR & ACR category combined together reflect risk of progression and helps Clinician to identify the individual who are progressing at more rapid rate than anticipated

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







		Dr. Vinay Chop MD (Pathology & Mic		Dr. Yugam	Chopra Pathology)	
	(Chairman & Consulta	ant Pathologis	t CEO & Consultant F	Pathologist	
NAME	: Mr. RAMESH	I CHAND				
AGE/ GENDER	: 45 YRS/MALI	Ε		PATIENT ID	: 1786923	
COLLECTED BY	:			REG. NO./LAB NO.	: 012503110018	
REFERRED BY	:			REGISTRATION DATE	: 11/Mar/2025 09:29 AM	
BARCODE NO.	:01526914			COLLECTION DATE	: 11/Mar/2025 09:35AM	
CLIENT CODE.	: KOS DIAGNO	STIC LAB		REPORTING DATE	: 11/Mar/2025 01:03PM	
CLIENT ADDRESS	: 6349/1, NICI	HOLSON ROAD, AMI	BALA CANTT			
Test Name			Value	Unit	Biological Reference in	ıterval
			IRON	PROFILE		
IRON: SERUM by FERROZINE, SPECTROPHOTOMETRY		,	130.01	μg/dL	59.0 - 158.0	
	UNSATURATED IRON BINDING CAPACITY (UIBC)		222.13	μg/dL	150.0 - 336.0	
:SERUM by FERROZINE, SPEC	TROPHOTOMETER	2Y				
		352.14	μg/dL	230 - 430		
:SERUM				10,		
by SPECTROPHOTOM		FRUM	36.92	%	15.0 - 50.0	
by CALCULATED, SPE			00.02	70	10.0 00.0	
TRANSFERRIN: SE			250.02	mg/dL	200.0 - 350.0	
INTERPRETATION:-	EIERT (FERENE)					
VARIAB	LES	ANEMIA OF CHROI	VIC DISEASE	IRON DEFICIENCY ANEMIA	THALASSEMIA α/β TRAIT	
SERUM IF	RON:	Normal to Re	duced	Reduced	Normal	

TOTAL IRON BINDING CAPACITY: Normal Decreased Increased % TRANSFERRIN SATURATION: Decreased Decreased < 12-15 % Normal **SERUM FERRITIN:** Normal to Increased Decreased Normal or Increased

IRON:

TEST PERFORMED AT KOS DIAGNOSTIC LAB. AMBALA CANTT

1.Serum iron studies is recommended for differential diagnosis of microcytic hypochromic anemia.i.e iron deficiency anemia, zinc deficiency

anemia, anemia of chronic disease and thalassemia syndromes.
 It is essential to isolate iron deficiency anemia from Beta thalassemia syndromes because during iron replacement which is therapeutic for iron deficiency anemia, is severely contra-indicated in Thalassemia.
 TOTAL IRON BINDING CAPACITY (TIBC): It is a direct measure of protein transferrin which transports iron from the gut to storage sites in the bone marrow.

% TRANSFERRIN SATURATION:

1. Occurs in idiopathic hemochromatosis and transfusional hemosiderosis where no unsaturated iron binding capacity is available for iron mobilization. Similar condition is seen in congenital deficiency of transferrin.





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







	Dr. Vinay Che MD (Pathology & Chairman & Cons	Microbiology)	M	m Chopra D (Pathology) nt Pathologist
NAME	: Mr. RAMESH CHAND			
AGE/ GENDER	: 45 YRS/MALE		PATIENT ID	: 1786923
COLLECTED BY	:		REG. NO./LAB NO.	: 012503110018
REFERRED BY	:		REGISTRATION DATE	: 11/Mar/2025 09:29 AM
BARCODE NO.	: 01526914		COLLECTION DATE	: 11/Mar/2025 09:35AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 11/Mar/2025 01:03PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, A	AMBALA CANT	Г	
Test Name		Value	Unit	Biological Reference interval
		ENDOC	CRINOLOGY	
	ТН	YROID FUN	CTION TEST: TOTAI	
TRIIODOTHYRONII	NE (T3): SERUM IESCENT MICROPARTICLE IMMUNOAS	1.21 SSAY)	ng/mL	0.35 - 1.93
THYROXINE (T4): S		6.59	μgm/d	L 4.87 - 12.60
THYROID STIMULA by CMIA (CHEMILUMIN	IESCENT MICROPARTICLE IMMUNOAS ATING HORMONE (TSH): SERU IESCENT MICROPARTICLE IMMUNOAS	M 7.649 ^H	µIU/m	L 0.35 - 5.50
3rd GENERATION, ULT. INTERPRETATION:	RASENSITIVE			
TSH levels are subject to o day has influence on the l triiodothyronine (T3).Fai	measured serum TSH concentrations. TS	H stimulates the p	roduction and secretion of the	pm. The variation is of the order of 50%.Hence time of t metabolically active hormones, thyroxine (T4)and her underproduction (hypothyroidism) or
CLINICAL CONDITION	T3		T4	TSH
Primary Hypothyroidis			Reduced	Increased (Significantly)
Subclinical Hypothyroi	dism: Normal or Low	Normal	Normal or Low Normal	High
Primary Hyperthyroidis	sm: Increased		Increased	Reduced (at times undetectable)
	NI I III I	N1 1	NU LICINI I	

LIMITATIONS:-

Subclinical Hyperthyroidism:

1. T3 and T4 circulates in reversibly bound form with Thyroid binding globulins (TBG), and to a lesser extent albumin and Thyroid binding Pre Albumin so conditions in which TBG and protein levels alter such as pregnancy, excess estrogens, androgens, anabolic steroids and glucocorticoids may falsely affect the T3 and T4 levels and may cause false thyroid values for thyroid function tests.

Normal or High Normal

Reduced

2. Normal levels of T4 can also be seen in Hyperthyroid patients with :T3 Thyrotoxicosis, Decreased binding capacity due to hypoproteinemia or ingestion of certain drugs (e.g.: phenytoin , salicylates).

3. Serum T4 levels in neonates and infants are higher than values in the normal adult , due to the increased concentration of TBG in neonate serum.

4. TSH may be normal in central hypothyroidism , recent rapid correction of hyperthyroidism or hypothyroidism , pregnancy , phenytoin therapy.

TRIIODOTH	(RONINE (T3)	DNINE (T3) THYROXINE (T4)		THYROID STIMULATING HORMONE (TSH)		
Age	Refferance Range (ng/mL)	Age	Refferance Range (µg/dL)	Age	Reference Range (µIU/mL)	
0-7 Days	0.20 - 2.65	0 - 7 Days	5.90 - 18.58	0 - 7 Days	2.43 - 24.3	
7 Days - 3 Months	0.36 - 2.59	7 Days - 3 Months	6.39 - 17.66	7 Days - 3 Months	0.58 - 11.00	
3 - 6 Months	0.51 - 2.52	3 - 6 Months	6.75 - 17.04	3 Days – 6 Months	0.70 - 8.40	
6 - 12 Months	0.74 - 2.40	6 - 12 Months	7.10 - 16.16	6 – 12 Months	0.70 - 7.00	

Normal or High Normal





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT





	Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Patholog		(Pathology)
NAME	: Mr. RAMESH CHAND		
AGE/ GENDER	: 45 YRS/MALE	PATIENT ID	: 1786923
COLLECTED BY	:	REG. NO./LAB NO.	: 012503110018
REFERRED BY	:	REGISTRATION DATE	: 11/Mar/2025 09:29 AM
BARCODE NO.	: 01526914	COLLECTION DATE	: 11/Mar/2025 09:35AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	: 11/Mar/2025 01:03PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANT	Т	
Test Name	Value	Unit	Biological Reference interval

i est name			value	UIII		Biological Reference interval
1 - 10 Years	0.92 - 2.28	1 - 10 Years	6.00 - 13.80	1 – 10 Years	0.60 - 5.50	
11- 19 Years	0.35 - 1.93	11 - 19 Years	4.87-13.20	11 – 19 Years	0.50 - 5.50	
> 20 years (Adults)	0.35 - 1.93	> 20 Years (Adults)	4.87 - 12.60	> 20 Years (Adults)	0.35-5.50	
	RECOM	MENDATIONS OF TSH LE	VELS DURING PRE	GNANCY (µIU/mL)		
	1st Trimester			0.10 - 2.50		
	2nd Trimester			0.20 - 3.00		
	3rd Trimester			0.30 - 4.10		

INCREASED TSH LEVELS:

1. Primary or untreated hypothyroidism may vary from 3 times to more than 100 times normal depending upon degree of hypofunction.

2. Hypothyroid patients receiving insufficient thyroid replacement therapy.

3. Hashimotos thyroiditis

4.DRUGS: Amphetamines, iodine containing agents & dopamine antagonist.

5.Neonatal period, increase in 1st 2-3 days of life due to post-natal surge

DECREASED TSH LEVELS:

1.Toxic multi-nodular goiter & Thyroiditis.

2. Over replacement of thyroid hormone in treatment of hypothyroidism.

3. Autonomously functioning Thyroid adenoma

4. Secondary pituitary or hypothalamic hypothyroidism

5. Acute psychiatric illness

6.Severe dehydration.

7.DRUGS: Glucocorticoids, Dopamine, Levodopa, T4 replacement therapy, Anti-thyroid drugs for thyrotoxicosis.

8. Pregnancy: 1st and 2nd Trimester





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.



NAME : Mr. RAMESH CHAND AGE/ GENDER : 45 YRS/MALE PATIENT ID : 1786923 COLLECTED BY :: REG.NO./LAB NO. : 012503110018 REFERRED BY :: REGISTRATION DATE : 11/Mar/2025 09:35M BARCODE NO. : 01526914 COLLECTION DATE : 11/Mar/2025 01:03PM CLIENT CODE : KOS DIAGNOSTIC LAB REPORTING DATE : 11/Mar/2025 01:03PM CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT INMAR / 2025 01:03PM CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT VITAMIN D /25 HYDROXY VITAMIN D/25 HYDROXY VITAMIN D3 VITAMIN D /25 HYDROXY VITAMIN D/25 HYDROXY VITAMIN D3 DEFICIENCY: < 20.0 INSUFFICIENCY: 30.0 - 100.0 TOXICITY: > 100.0 NUTERPRETATION: :: :: :: SUTFICIENCY: : :< : : NUTAMIN D (25 HYDROXY VITAMIN D3): SERUM 19.435 ^L ng/mL INSUFFICIENCY: : :< :			Dr. Vinay Ch MD (Pathology & Chairman & Cor			Yugam Cho MD (Patholo onsultant Patholo	ogy)
COLLECTED BY: REG. NO./LAB NO. : 012503110018 REFERRED BY: REGISTRATION DATE : 11/Mar/2025 09:29 AM BARCODE NO. : 01520914 COLLECTION DATE : 11/Mar/2025 09:35AM CLIENT CODE :: KOS DIAGNOSTIC LAB REPORTING DATE : 11/Mar/2025 09:35AM CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT Biological Reference interva VITAMINS VITAMIN D/25 HYDROXY VITAMIN D3 VITAMIN D/25 HYDROXY VITAMIN D3 OUTORING PARTY WITAMINESCENCE MMUNIOASSAN? 0.01/MIL 0.01/MIL OUTORING PARTY VITAMIN D (25-HYDROXY VITAMIN D3): SERUM 0.9439 ¹ 0.01/MIL 0.01/MIL OUTORING PARTY VITAMIN D (25-HYDROXY VITAMIN D3): SERUM 0.9430 ¹ 0.01/MIL MIL OUTORING PARTY NOTORING PARTY OUTORING PARTY OUTORING PARTY OUTORING PARTY<	AME	: Mr. RAMESH	I CHAND				
DELECTED BY E. REG. NO./LAB NO. : 012503110018 SEFERRED BY :: REGISTRATION DATE : 11/Mar/2025 09:29 AM AARCODE NO. :: 01526914 COLLECTION DATE :: 11/Mar/2025 09:25 AM LIENT CODE :: KOS DIAGNOSTIC LAB REPORTING DATE :: 11/Mar/2025 01:03 PM LIENT ADDRESS :: : :	GE/ GENDER	: 45 YRS/MAL	E		PATIENT ID	: 178	36923
EFERRED BY E. ERGISTRATION DATE 11/Mar/2025 09:29 AM ARCODE NO. :01526914 COLLECTION DATE :11/Mar/2025 09:35 AM LIENT CODE :KOS DIAGNOSTIC LAB REPORTING DATE :11/Mar/2025 01:03 PM LIENT ADDRESS :6349/1, NICHOLSON ROAD, AMBALA CANTT Biological Reference interva VITAMINS VITAMIN D2:5 HYDROXY VITAMIN D3 TAMIN D/25 HYDROXY VITAMIN D3 TAMIN D/25 HYDROXY VITAMIN D3 CILIPONE VITAMIN D3: SERUM by CLA (CHEMILUMINESCENCE IMMUNOASSAY) INSUFFICIENCY: < 20.0		•					
ARCODE NO. : : 01526914		•					
LIENT CODE : KOS DIACNOSTIC LAB REPORTING DATE : 11/Mar/2025 01:03PM LIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT 'est Name Value Unit Biological Reference interva LIENT COLE : WITAMIND /25 HYDROXY VITAMIN D3 VITAMIN D/25 HYDROXY VITAMIN D3 TAMIN D (25-HYDROXY VITAMIN D3): SERUM 19.435 ^L ng/mL DEFICIENCY: 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0 TOXICITY: > 100.0 by CLIA (CHEMALUMINESCENCE IMMUNOASSAY) 19.435 ^L ng/mL DEFICIENCY: 30.0 - 100.0 SUFFICIENCY: 30.0 - 100.0 SUFFICIENCY: 30.0 - 100.0 TOXICITY: > 100.0 VIERPRETATION: < 20		• 01526914					
LIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT est Name Value Unit Biological Reference interval LIENT ADDRESS Value Unit Biological Reference interval LIENT ADDRESS VITAMIND Vitamin D/25 HyDROXY VITAMIN D3): Exception TAMIN D (25-HYDROXY VITAMIN D3): SERUM 19,435 ^L ng/mL DEFICIENCY: 20.0 - 30.0 SUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 20.0 - 100.0 TOXICITY : 100.0 THEPRETATION: No DEFICIENT: 0.0 - 100.0 SUFFICIENCY: 20.0 - 100.0 SUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 20.0 - 100.0 SUFFICIENCY: 20.			STIC I AB				
VITAMINS VITAMIN D/25 HYDROXY VITAMIN D3 TAMIN D/25 HYDROXY VITAMIN D3 TAMIN D/25 HYDROXY VITAMIN D3): SERUM by CLA (CHEMILUMINESCENCE IMMUNOASSAY) by CLA (CHEMILUMINESCENCE IMMUNOASSAY) DEFICIENCY: 20.0 - 30.0 SUFFICIENCY: 20.0 - 30.0 SUFFICIENT: 0 MISUFFICIENT: 20 M/mL NUTERPRETATION: VIEPPRETATION: VIEPTRETATION: VIEPTRETATION: VIEPTRETATION: VIEPTRETATION:				AMBALA CANTT			1417 2020 01.001 W
VITAMIN D/25 HYDROXY VITAMIN D3 TAMIN D (25-HYDROXY VITAMIN D3): SERUM by CLA (CHEMILUMINESCENCE IMMUNOASSAY) 19.435 ^L ng/mL DEFICIENCY: < 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0 TOXICITY: > 100.0 VITERPRETATION: NTERPRETATION: NTOXICITY: > 100.0 NOTICITY: > 20.0 NOTICITY: > 100.0	'est Name			Value	U	nit	Biological Reference interval
DEFICIENT: < 20	by CLIA (CHEMILUMIN			1 19.435 ^L	nş	g/mL	INSUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0
PREFFERED RANGE: 30 - 100 ng/mL INTOXICATION: > 100 ng/mL Vitamin D compounds are derived from dietary eraocalciferol (from plants, Vitamin D2), or cholecalciferol (from animals, Vitamin D3), or by inversion of 7 - dihydrocholecalciferol to Vitamin D3 in the skin upon Ultraviolet exposure. 25-OHVitamin D represents the main body resevoir and transport form of Vitamin D and transport form of Vitamin D, being stored in adiports sue and tightly bound by a transport protein while in circulation. Vitamin D plays a primary role in the maintenance of calcium homeostatis. It promotes calcium absorption, renal calcium absorption and nosphate reabsorption, skeletal calcium deposition, calcium mobilization, mainly regulated by parathyroid harmone (PTH). Severe deficiency may lead to failure to mineralize newly formed osteoid in bone, resulting in rickets in children and osteomalacia in adults CREASED : Lack of sunshine exposure. Inadequate Intake, malabsorption (celiac disease) Depressed Hepatic Vitamin D 25- hydroxylase activity Secondary to advanced Liver disease Osteoporosis and Secondary Hyperparathroidism (Mild to Moderate deficiency) Enzyme Inducing drugs: anti-epileptic drugs like phenytoin, phenobarbital and carbamazepine, that increases Vitamin D metabolism. CREASED: Hypervitaminosis D is Rare, and is seen only after prolonged exposure to extremely high doses of Vitamin D. When it occurs, it can result in vere hypercalcemia and hyperphophatemia. <td< td=""><th></th><td>CIENT:</td><td></td><td>< 20</td><td></td><td>ng/mL</td><td></td></td<>		CIENT:		< 20		ng/mL	
INTOXICATION: > 100 ng/mL Vitamin D compounds are derived from dietary ergocalciferol (from plants, Vitamin D2), or cholecalciferol (from animals, Vitamin D3), or by inversion of 7- dihydrocholecalciferol to Vitamin D in the skin upon Ultraviolet exposure. 25-OHVitamin D represents the main body resevoir and transport form of Vitamin D and transport form of Vitamin D, being stored in adiptive a transport portein while in circulation. Vitamin D plays a primary role in the maintenance of calcium homeostatis. It promotes calcium absorption, renal calcium absorption and tosphate reabsorption, skeletal calcium deposition, calcium mobilization, mainly regulated by parathyroid harmone (PTH). Severe deficiency may lead to failure to mineralize newly formed osteoid in bone, resulting in rickets in children and osteomalacia in adults CREASED : Lack of sunshine exposure. Inadequate intake, malabsorption (celiac disease) Depressed Hepatic Vitamin D 25- hydroxylase activity Secondary to advanced Liver disease Osteoporosis and Secondary Hyperparathroidism (Mild to Moderate deficiency) Enzyme Inducing drugs: anti-epileptic drugs like phenytoin, phenobarbital and carbamazepine, that increases Vitamin D metabolism. CREASED: Hypervitaminosis D is Rare, and is seen only after prolonged exposure to extremely high doses of Vitamin D. When it occurs, it can result in vere hypercalcemia and hyperphophatemia. UUTION: Replacement therapy in deficient individuals must be monitored by periodic assessment of Vitamin D. When it order to prevent 'pervitaminosis D DTE:-Dark coloured ind						9	
Vitamin D compounds are derived from dietary ergocalciferol (from plants, Vitamin D2), or cholecalciferol (from animals, Vitamin D3), or by proversion of 7- dihydrocholecalciferol to Vitamin D3 in the skin upon Ultraviolet exposure. 25-OHVitamin D represents the main body resevoir and transport form of Vitamin D and transport form of Vitamin D, being stored in adiptives and tightly bound by a transport protein while in circulation. Vitamin D plays a primary role in the maintenance of calcium homeostatis. It promotes calcium absorption, renal calcium absorption and hosphate reabsorption, skeletal calcium deposition, calcium mobilization, mainly regulated by parathyroid harmone (PTH). Severe deficiency may lead to failure to mineralize newly formed osteoid in bone, resulting in rickets in children and osteomalacia in adults CREASED: Lack of sunshine exposure. Inadequate intake, malabsorption (celiac disease) Depressed Hepatic Vitamin D 25- hydroxylase activity Secondary to advanced Liver disease Osteoporosis and Secondary Hyperparathroidism (Mild to Moderate deficiency) Enzyme Inducing drugs: anti-epileptic drugs like phenytoin, phenobarbital and carbamazepine, that increases Vitamin D metabolism. (CREASED: Hypervitaminosis D is Rare, and is seen only after prolonged exposure to extremely high doses of Vitamin D. When it occurs, it can result in your hyperparate therapy in deficient individuals must be monitored by periodic assessment of Vitamin D levels in order to prevent yoervitaminosis D OTE: - <i>Dark coloured individuals as compare to whites, is at higher risk of developing Vitamin D deficiency due to excess of melanin pigment which</i>							
	onversion of 7- dihy .25-OHVitamin D r ssue and tightly bou .Vitamin D plays a p hosphate reabsorpt .Severe deficiency n ECREASED: .Lack of sunshine ex .Inadeguate intake, .Depressed Hepatic .Secondarv to advar .Osteoporosis and S .Enzyme Inducing di VCREASED: . Hypervitaminosis D evere hypercalcemia AUTION: Replaceme OPE:-Dark coloured	drocholecalcifer epresents the m und by a transpo- rimary role in the ion, skeletal cale hay lead to failur posure. malabsorption (Vitamin D 25- ho neced Liver diseas econdary Hyper rugs: anti-epilep D is Rare, and is so and hyperphop ent therapy in de individuals as cor	ol to Vitamin D ain body resevo rt protein while le maintenance cium deposition re to mineralize (celiac disease) vdroxylase activ e parathroidism (l tic drugs like ph seen only after p hatemia. ficient individua	3 in the skin upon ir and transport for of calcium homeon , calcium mobilization newly formed ost ity Mild to Moderate enytoin, phenobation prolonged exposution	Ultraviolet exposu orm of Vitamin D ar ostatis. It promotes titon, mainly regula teoid in bone, resul deficiency) rbital and carbama re to extremely hig pred by periodic as:	re. nd transport for s calcium absor ited by parathy ting in rickets in zepine, that inc h doses of Vitar sessment of Vita	m of Vitamin D, being stored in adipose ption, renal calcium absorption and roid harmone (PTH). In children and osteomalacia in adults. Preases Vitamin D metabolism. min D. When it occurs, it can result in amin D levels in order to prevent

KOS Diagnostic Lab (A Unit of KOS Healthcare)





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







		hopra & Microbiology) onsultant Pathologist	Dr. Yugam MD CEO & Consultant	(Pathology)		
NAME	: Mr. RAMESH CHAND					
AGE/ GENDER	: 45 YRS/MALE	PATIE	INT ID	: 1786923		
COLLECTED BY	:	REG. NO./LAB NO. : 012503110018				
REFERRED BY		REGIS	TRATION DATE	: 11/Mar/2025 09:29 AM		
BARCODE NO.	: 01526914		ECTION DATE	: 11/Mar/2025 09:35AM		
CLIENT CODE.	: KOS DIAGNOSTIC LAB		RTING DATE	: 11/Mar/2025 01:03PM		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD), AMBALA CANTT				
Test Name		Value	Unit	Biological Reference interval		
by CMIA (CHEMILUMII	BALAMIN: SERUM Nescent microparticle immuno	126.2^L ASSAY)	pg/mL	190.0 - 830		
by CMIA (CHEMILUMII INTERPRETATION:-	NESCENT MICROPARTICLE IMMUNO	ASSAY)				
by CMIA (CHEMILUMII INTERPRETATION:- INCREA	NESCENT MICROPARTICLE IMMUNO SED VITAMIN B12	ASSAY)	DECREASED VITAMIN			
by CMIA (CHEMILUMII INTERPRETATION:- INCREA 1.Ingestion of Vitar	NESCENT MICROPARTICLE IMMUNO SED VITAMIN B12 min C	ASSAY)	DECREASED VITAMIN	B12		
by CMIA (CHEMILUMII INTERPRETATION:- INCREA 1.Ingestion of Vitar 2.Ingestion of Estro	NESCENT MICROPARTICLE IMMUNO SED VITAMIN B12 min C ogen	ASSAY) 1.Pregnancy 2.DRUGS:Aspiri	DECREASED VITAMIN	B12		
by CMIA (CHEMILUMII INTERPRETATION:- INCREA 1.Ingestion of Vitar	NESCENT MICROPARTICLE IMMUNO SED VITAMIN B12 min C ogen nin A	ASSAY)	DECREASED VITAMIN	B12		
by CMIA (CHEMILUMII INTERPRETATION:- INCREA 1.Ingestion of Vitar 2.Ingestion of Vitar 3.Ingestion of Vitar 4.Hepatocellular in 5.Myeloproliferativ	NESCENT MICROPARTICLE IMMUNO SED VITAMIN B12 min C ogen nin A njury	ASSAY) 1.Pregnancy 2.DRUGS:Aspiri 3.Ethanol Igesti 4. Contraceptiv 5.Haemodialys	DECREASED VITAMIN n, Anti-convulsants, ion e Harmones is	B12		
by CMIA (CHEMILUMII INTERPRETATION:- INCREA 1.Ingestion of Vitar 2.Ingestion of Vitar 3.Ingestion of Vitar 4.Hepatocellular ir 5.Myeloproliferativ 6.Uremia 1.Vitamin B12 (coba	NESCENT MICROPARTICLE IMMUNO SED VITAMIN B12 min C ogen nin A njury	ASSAY)	DECREASED VITAMIN n, Anti-convulsants, ion e Harmones is eloma hal function.	B12 Colchicine		





DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.





	Dr. Vinay Cho MD (Pathology & Chairman & Cons	Microbiology)	Dr. Yugam MD O & Consultant	(Pathology)
NAME	: Mr. RAMESH CHAND			
AGE/ GENDER	: 45 YRS/MALE	PATIENT 1	D	: 1786923
COLLECTED BY	:	REG. NO./2	LAB NO.	: 012503110018
REFERRED BY	:	REGISTRA	TION DATE	: 11/Mar/2025 09:29 AM
BARCODE NO.	:01526914	COLLECTI		: 11/Mar/2025 09:35AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTIN	IG DATE	: 11/Mar/2025 10:00AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, A	AMBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
		CLINICAL PATHO	LOGY	
	URINE RO	UTINE & MICROSCOP		ATION
PHYSICAL EXAMIN	IATION			
QUANTITY RECIEVI		10	ml	
COLOUR	TANCE SPECTROPHOTOMETRY	AMBER YELLOW		PALE YELLOW
by DIP STICK/REFLECT	TANCE SPECTROPHOTOMETRY	CLEAR		CLEAR
	TANCE SPECTROPHOTOMETRY	ULEAR		
SPECIFIC GRAVITY	TANCE SPECTROPHOTOMETRY	<=1.005		1.002 - 1.030
CHEMICAL EXAMI				
REACTION		ACIDIC		
PROTEIN	TANCE SPECTROPHOTOMETRY	Negative		NEGATIVE (-ve)
,	TANCE SPECTROPHOTOMETRY	-		
SUGAR by DIP STICK/REFLECT	TANCE SPECTROPHOTOMETRY	Negative		NEGATIVE (-ve)
pH	TANCE SPECTROPHOTOMETRY	6		5.0 - 7.5
BILIRUBIN		Negative		NEGATIVE (-ve)
by DIP STICK/REFLECT NITRITE	TANCE SPECTROPHOTOMETRY	Negative		NEGATIVE (-ve)
by DIP STICK/REFLEC	TANCE SPECTROPHOTOMETRY.			
UROBILINOGEN by DIP STICK/REFLECT	TANCE SPECTROPHOTOMETRY	Normal	EU/dL	0.2 - 1.0
KETONE BODIES		Negative		NEGATIVE (-ve)
by DIP STICK/REFLECT	TANCE SPECTROPHOTOMETRY	Negative		NEGATIVE (-ve)
-	TANCE SPECTROPHOTOMETRY			
ASCORBIC ACID by DIP STICK/REFLECT	TANCE SPECTROPHOTOMETRY	NEGATIVE (-ve)		NEGATIVE (-ve)
MICROSCOPIC EXA				
RED BLOOD CELLS	(RBCs)	NEGATIVE (-ve)	/HPF	0 - 3



DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com
 www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.





Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME	: Mr. RAMESH CHAND		
AGE/ GENDER	: 45 YRS/MALE	PATIENT ID	: 1786923
COLLECTED BY	:	REG. NO./LAB NO.	: 012503110018
REFERRED BY	:	REGISTRATION DATE	: 11/Mar/2025 09:29 AM
BARCODE NO.	: 01526914	COLLECTION DATE	: 11/Mar/2025 09:35AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	: 11/Mar/2025 10:00AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		
Test Name	Value	Unit	Biological Reference interval
by MICROSCOPY ON (CENTRIEUGED URINARY SEDIMENT		

by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT			
PUS CELLS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	2-3	/HPF	0 - 5
EPITHELIAL CELLS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	1-2	/HPF	ABSENT
CRYSTALS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
CASTS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
BACTERIA by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
OTHERS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
TRICHOMONAS VAGINALIS (PROTOZOA) by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	ABSENT		ABSENT

** End Of Report ***





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

V DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

